Archives of Medical Research
Volume 41, Issue 3 , Pages 207-214, April 2010

Two Novel Mutations in SCN1A Gene in Iranian Patients with Epilepsy

  • Ahmad Ebrahimi

      Affiliations

    • National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
  • ,
  • Massoud Houshmand

      Affiliations

    • National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
    • Corresponding Author InformationAddress reprint requests to: Dr. Massoud Houshmand, PhD, Genetic Disease Department, National Institute of Genetic Engineering and Biotechnology, Shahrak-e Pajohesh, km 15, Tehran-Karaj Highway, P.O. Box 14965/161, Tehran, Iran; Phones: (+98) 21 44580301-27, (+98) 21 44580396 & 98
  • ,
  • Seyed Hassan Tonekaboni

      Affiliations

    • Shahid Beheshti, University of Medical Sciences (SBMU), Tehran, Iran
  • ,
  • Mohammd Sadegh Fallah Mahboob Passand

      Affiliations

    • National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
  • ,
  • Sirous Zainali

      Affiliations

    • Biotechnology Department, Pasteur Institute of Iran (IPI), Tehran, Iran
  • ,
  • Mehdi Moghadasi

      Affiliations

    • Department of Neurology, Iran University of Medical Sciences, Tehran, Iran

Received 15 October 2009; accepted 26 January 2010.

(ARCMED-D-00489)

Background and Aims

Epilepsy as a common chronic neurological disorder is characterized by recurrent unprovoked seizures. Febrile seizures are the most common type of epilepsy in infants and children. Our aim was the molecular analysis of SCN1A gene in affected Iranian patients with GEFS+ and Dravet syndrome diagnosed clinically to explain genotype−phenotype correlation and exact classification.

Methods

The 34 unrelated Iranian families with epilepsy were selected and screened for SCN1A mutations by MLPA, ARMS, and PCR-RFLP confirmed by direct sequencing.

Results

MLPA analysis showed normal patterns, but direct sequencing revealed that generally 20/34 (0.588) probands have common reported single nucleotide polymorphisms (SNPs) (p.A1067G; rs2298771) with allelic frequency as 0.706/0.294 in patients and 0.515/0.485 in control group, respectively, for A/G. No significant differences between groups were observed. Moreover, four novel allelic variants as missense substitutions included two new sequence variation (p.F412 I, p.Y1274N) and two previously reported mutations (p.R101G, p.S103G) that were detected in 4/34 probands but not in control groups and other healthy normal family members.

Conclusions

Clinical diagnosis could nearly establish the classification, but mutation screening helps clinicians to confirm their data. We found mutation in four probands and confirmed the net diagnosis. Our data suggest that the clinical symptom variations could be also explained, considering the role of modifier genes such as mitochondrial mutations or other genes responsible for drug metabolism pathways including multiple drug resistance family genes (ABCB1) or MTHFR.

Key Words: Epilepsy, SCN1A, Severe myoclonic epilepsy of infancy, Generalized epileptic febrile seizures plus, Multiplex ligation-dependent probe amplification

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0188-4409(10)00098-6

doi:10.1016/j.arcmed.2010.04.007

Archives of Medical Research
Volume 41, Issue 3 , Pages 207-214, April 2010